Abstract
Devising therapies for neurodegenerative diseases remains a major challenge due to the complex etiology, prolonged disease course and the paucity of validated targets. These factors make it difficult to model neurodegenerative diseases in a manner amenable to large-scale screening. However, recent developments in automation, combinatorial chemistry and high-throughput phenotypic assays have presented new opportunities for discovering small molecule therapeutics for neurodegenerative diseases. This review focuses on novel in vitro and phenotypic screens for Huntingtons disease and a few other neurodegenerative diseases. The lessons learned from these screens and the potential of the small molecules identified as therapeutic leads are discussed.
Keywords: Drug discovery, huntington's disease, models, polyglutamine disease, screening, therapy, Amyotrophic Lateral Sclerosis, ALS, SMER's, small molecule enhancers of rapamy, synuclein, FGF-2, CNTF, brain derived growth factor, BDNF, Fluorescence Resonance Energy transfer, FRET, Y-27632, spinocerebellar ataxia-1, SCA-1, su-peroxide dismutase, SOD, caffeic acid phenylethyl ester, CAPE
Current Molecular Pharmacology
Title: Drug Screening for Huntingtons Disease and other Neurodegenerative Disorders
Volume: 3
Author(s): Hemant Varma
Affiliation:
Keywords: Drug discovery, huntington's disease, models, polyglutamine disease, screening, therapy, Amyotrophic Lateral Sclerosis, ALS, SMER's, small molecule enhancers of rapamy, synuclein, FGF-2, CNTF, brain derived growth factor, BDNF, Fluorescence Resonance Energy transfer, FRET, Y-27632, spinocerebellar ataxia-1, SCA-1, su-peroxide dismutase, SOD, caffeic acid phenylethyl ester, CAPE
Abstract: Devising therapies for neurodegenerative diseases remains a major challenge due to the complex etiology, prolonged disease course and the paucity of validated targets. These factors make it difficult to model neurodegenerative diseases in a manner amenable to large-scale screening. However, recent developments in automation, combinatorial chemistry and high-throughput phenotypic assays have presented new opportunities for discovering small molecule therapeutics for neurodegenerative diseases. This review focuses on novel in vitro and phenotypic screens for Huntingtons disease and a few other neurodegenerative diseases. The lessons learned from these screens and the potential of the small molecules identified as therapeutic leads are discussed.
Export Options
About this article
Cite this article as:
Varma Hemant, Drug Screening for Huntingtons Disease and other Neurodegenerative Disorders, Current Molecular Pharmacology 2010; 3 (3) . https://dx.doi.org/10.2174/1874467211003030164
DOI https://dx.doi.org/10.2174/1874467211003030164 |
Print ISSN 1874-4672 |
Publisher Name Bentham Science Publisher |
Online ISSN 1874-4702 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neuroinflammation as a Common Mechanism Associated with the Modifiable Risk Factors for Alzheimer’s and Parkinson’s Diseases
Current Aging Science Interplay between the APOE Genotype and Possible Plasma Biomarkers in Alzheimer’s Disease
Current Alzheimer Research Astrocytes Pathology in ALS: A Potential Therapeutic Target?
Current Pharmaceutical Design Plant Polyphenols and Oral Health: Old Phytochemicals for New Fields
Current Medicinal Chemistry Melatonin and Related Compounds: Chemical Insights into their Protective Effects Against Oxidative Stress
Current Organic Chemistry Cell Cycle Regulatory Protein 5 (Cdk5) is a Novel Downstream Target of ERK in Carboplatin Induced Death of Breast Cancer Cells (Supplementary Data)
Current Cancer Drug Targets Nanocarriers Assisted siRNA Gene Therapy for the Management of Cardiovascular Disorders
Current Pharmaceutical Design Potential Effects of Cannabidiol as a Wake-Promoting Agent
Current Neuropharmacology Prolyl-Specific Peptidases and Their Inhibitors in Biological Processes
Current Chemical Biology Molecular Genetics and Biomarkers of Polyglutamine Diseases
Current Molecular Medicine Gastric Inhibitory Polypeptide and its Receptor are Expressed in the Central Nervous System and Support Neuronal Survival
Central Nervous System Agents in Medicinal Chemistry A Scientific Approach to Anti-Ageing Therapies: State of the Art
Current Pharmaceutical Design RNA Interference and Amyotrophic Lateral Sclerosis
Current Drug Metabolism Natural and Synthetic Inhibitors of Caspases: Targets for Novel Drugs
Current Drug Targets - CNS & Neurological Disorders Ginger and Heart Health: From Mechanisms to Therapeutics
Current Molecular Pharmacology Control and Role of Plateau Potential Properties in the Spinal Cord
Current Pharmaceutical Design Frontotemporal Dementia Caused by CHMP2B Mutations
Current Alzheimer Research Update on Myositis Therapy: From Today’s Standards to Tomorrow’s Possibilities
Current Pharmaceutical Design Scope of Lipid Nanoparticles in Neuroscience: Impact on the Treatment of Neurodegenerative Diseases
Current Pharmaceutical Design Recent Progress in Gene Therapy for Parkinson’s Disease
Current Molecular Medicine